Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AstraZeneca ( (GB:AZN) ) just unveiled an update.
AstraZeneca has confirmed that, as of 31 January 2026, its issued share capital with voting rights stands at 1,550,944,612 ordinary shares, with no shares held in treasury, resulting in a total of 1,550,944,612 voting rights in the company. This updated capital and voting rights figure, published in line with UK Financial Conduct Authority disclosure rules, provides investors with the key denominator needed to assess and report any changes in their shareholdings, reinforcing transparency and regulatory compliance in the company’s shareholder base.
More about AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company based in Cambridge, UK, focused on the discovery, development and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology, with products sold in more than 125 countries and used by millions of patients worldwide.
For an in-depth examination of AZN stock, go to TipRanks’ Overview page.